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Asthma is one of the most common chronic diseases 
of adults and children, and with the prevalence 
increasing in many regions, it is now considered to be 
a major public health problem in industrialised 
countries. Asthma is now recognised as an inflamma- 
tory condition of the airways that is associated with 
increased responsiveness to a variety of bronchial 
stimuli. Acute and chronic inflammation and airway 
remodelling in bronchial asthma causes progressive 
airway damage and irreversible airway obstruction. 
Today, the possibility of achieving and maintaining 
asthma control in the vast majority of patients is 
extremely good, and this is the result of therapy based 
mainly on inhaled corticosteroids and P,-agonists. 
The receptor sites for the therapeutic action of 
these drugs are distributed throughout the airways. 
Studies have shown that the clinical effects of a drug 
are related to the amount reaching the lung, as well as 
the distribution of the inhaled dose throughout the 
lung. The site and magnitude of airways obstruction 
influences inhaled drug deposition and distribution. 
Hence, in addition to the actual dose, the pharma- 
ceutical performance of a delivery system and the 
characteristics of the emitted inhaled product, 
together with the patient’s inhalation technique, 
determine the amount of drug deposited and the drug 
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distribution in the lung. All of these parameters have 
to be reproducible and consistent during long-term 
clinical use in order to achieve effective asthma 
management. 
This supplement examines the pathology of respir- 
atory disease, focusing on the processes involved and 
the potential targets for drug therapy, with a separate 
discussion on the relative importance of central and 
peripheral inflammation in asthma. This is followed 
by a review of the pharmaceutical performance of 
inhaler devices and general factors influencing drug 
delivery to the lung. The relative importance of total 
particle dose and particle distribution to the clinical 
effect of an inhaled drug will be discussed, based on 
present knowledge. The clinical pharmacokinetics 
and pharmacodynamics of different inhaled cortico- 
steroids, and the relevance of these properties to 
clinical efficacy and safety is summarised. The follow- 
ing articles focus on local and systemic effects and 
methods of assessing efficacy and safety of inhaled 
drugs. The final section examines the clinical effec- 
tiveness of inhaled products in the treatment of 
asthma and the efficacy : safety ratio of these drugs. 
Clinical issues related to the use of inhaled 
&-agonists and inhaled corticosteroids in adults and 
children with asthma are also discussed. 
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